Dr. Janette Nesheiwat of Family for Emergency Care applauds President Trump for securing 100 percent of brakes for the month of July and 90 percent for August and September, because there is now a shortage of medicine.
Gilead Sciences Inc. said on Monday that it has submitted a marketing application to the U.S. Food and Drug Administration for its experimental COVID-19 drug inhibitor.
The antiviral medication, available under the brand name Veklury, is one of the few treatments that have been shown to be effective against respiratory disease.
FAT FOX BUSINESS ON THE GO BY CLICK HERE
The treatment has received the approval of the US health regulator for emergency use in patients with hospitalization with severe COVID-19.
The marketing application is supported by data from two late-stage human trials conducted by Gilead and another late-stage trial by the National Institute of Allergy and Infectious Diseases, the company said.
CLICK HERE TO READ MORE ABOUT FOXBUSINESS
The drug has been at the forefront in the fight against respiratory disease, after the invenvenos administration medicine helped hospital recovery times in a U.S. trial.
Remdesivir is approved by several regulatory authorities around the world, including in the European Union and Japan.
